The purpose of this survey is to provide the Canadian Cancer Survivor Network (CCSN) with insights and perspectives about Keytruda (pembrolizumab) for the treatment of adult patients with metastatic cervical cancer who are being treated with systemic therapies.
If you are a patient outside of this specification and feel you may also benefit from this treatment, we would like to hear from you as well.
The pan-Canadian Oncology Drug Review invites patient groups like CCSN to prepare submissions so that patients like you can be heard. Please join us and have your voice included in this important submission process.
Thank you for your participation.